Pliant Therapeutics, Inc.
PLRX
Rank in Stocks
#22807
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical... Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avร6 and avร1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avร1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Share Price
$0.7996
Last synced: 2026-11-09
Market Cap
$49.51M
Change (1 day)
-1.25%
Change (1 year)
-52.12%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Pliant Therapeutics, Inc. (PLRX)
Category
Healthcare
Operating Margin for Pliant Therapeutics, Inc. (PLRX)
Operating Margin as of November 2026 TTM: 0.00%
According to Pliant Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Pliant Therapeutics, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -11,654.75% | 787.39% |
| 2022 | -1,313.37% | 1.96% |
| 2021 | -1,288.10% | 1,193.40% |
| 2020 | -99.59% | 4,510.65% |
| 2019 | -2.16% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pliant Therapeutics, Inc.'s operating margin
What was Pliant Therapeutics, Inc.'s operating margin in 2025?
In 2025, Pliant Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Pliant Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Pliant Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-11,654.75%).
How does Pliant Therapeutics, Inc.'s operating margin compare with similar companies?
Pliant Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.